We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Cue Biopharma Inc
2 own
4 watching
Current Price
$3.74
$0.02
(0.54%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
132.34M
52-Week High
7.455
52-Week Low
2.18
Average Volume
0.04M
Dividend Yield
--
P/E Ratio
--
Market Capitalization132.34M52-Week High7.45552-Week Low2.18Average Volume0.04MDividend Yield--P/E Ratio--What does the Cue Biopharma Inc do?
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cue Biopharma Inc make?
News & Events about Cue Biopharma Inc.
Globe Newswire
7days ago
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patients body, announced today that its President ...
Globe Newswire
16days ago
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel ...
Globe Newswire
2 months ago
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body, announced today that it will take part ...
Globe Newswire
2 months ago
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body, announced today that it has entered ...
Globe Newswire
3 months ago
Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 at the recommended Phase 2 dose and pembrolizumab.Median overall survival (mOS) approaching greater than 12 months in third line ...
Frequently Asked Questions
Frequently Asked Questions
What is Cue Biopharma Inc share price today?
Can Indians buy Cue Biopharma Inc shares?
How can I buy Cue Biopharma Inc shares from India?
Can Fractional shares of Cue Biopharma Inc be purchased?
What are the documents required to start investing in Cue Biopharma Inc stocks?
What is today’s traded volume of Cue Biopharma Inc?
What is today’s market capitalisation of Cue Biopharma Inc?
What is the 52-Week High and Low Range of Cue Biopharma Inc?
What percentage is Cue Biopharma Inc down from its 52-Week High?
What percentage is Cue Biopharma Inc up from its 52-Week Low?
Current Price
$3.74
$0.02
(0.54%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.